vaccin
research
center
develop
vaccin
candid
differ
diseasesinfecti
agent
includ
ebola
marburg
virus
built
adenoviru
vector
platform
base
adenoviru
type
support
clinic
develop
vaccin
candid
preclin
studi
perform
rabbit
determin
bodi
biodistribut
rapidli
clear
screen
potenti
toxic
intrins
immunotox
vaccin
biodistribut
spleen
liver
andor
iliac
lymph
node
otherwis
remain
site
inject
muscl
overli
subcuti
though
viral
particl
inocul
alreadi
day
genom
copi
per
dna
clear
inject
site
muscl
three
month
adenovector
clear
anim
retain
small
number
copi
inject
site
spleen
iliac
lymph
node
pattern
limit
biodistribut
extens
clearanc
consist
regardless
differ
adenovector
type
manufactur
construct
product
method
geneinsert
repeat
dose
toxicolog
studi
identifi
treatmentrel
toxic
confin
primarili
site
inject
certain
clinic
patholog
paramet
bodi
temperatur
vector
food
consumpt
immedi
postinocul
system
reactogen
reactogen
site
inject
demonstr
revers
data
demonstr
safeti
suitabl
investig
human
use
adenovectorbas
vaccin
candid
dose
given
intramuscularli
prevent
variou
infecti
diseas
adenoviru
ad
vector
vaccin
candid
novel
product
class
began
test
clinic
prevent
infecti
diseas
indic
start
earli
initi
candid
base
adenoviru
type
howev
newer
preclin
clinic
candid
base
altern
adenoviru
serotyp
chimer
construct
design
intent
circumv
high
degre
preexist
immun
human
popul
factor
safeti
issu
prove
reduc
util
vector
current
clinic
test
thorner
et
al
novel
product
class
repres
uniqu
regulatori
challeng
order
advanc
preclin
candid
forward
clinic
preclin
safeti
evalu
need
conduct
determin
bodi
adenovector
would
biodistribut
intramuscular
inocul
order
identifi
potenti
target
organ
toxic
whether
toxicolog
effect
could
identifi
effect
might
either
direct
intrins
toxic
adenovector
immunotox
result
host
immun
respons
vaccin
insert
adenovector
antigen
brief
discuss
vaccineinduc
immunotox
see
sheet
et
al
frequent
vaccineinduc
advers
reaction
toxic
gener
refer
reactogen
refer
way
throughout
articl
includ
local
reaction
site
inject
pain
tender
erythema
indur
system
reaction
fever
fatigu
malais
myalgia
headach
nausea
vomit
inappet
etc
reactogen
often
consequ
intend
unintend
immun
respons
inflamm
induc
vaccin
vaccin
larg
safe
must
given
administ
healthi
individu
prevent
potenti
futur
diseas
side
effect
seen
vaccin
typic
type
local
system
reactogen
thu
preclin
safeti
assess
vaccin
candid
support
clinic
investig
must
address
type
sever
reactogen
expect
vaccin
well
identifi
potenti
safeti
signal
might
unusu
particular
vaccin
candid
rabbit
chosen
test
model
studi
speci
larg
enough
receiv
full
human
dose
vaccin
import
sinc
immunogen
andor
pharmaceut
effect
vaccin
scale
directli
bodi
weight
bodi
surfac
area
may
case
drug
dissemin
blood
part
bodi
vaccin
act
local
site
inject
deliv
parenter
induc
immun
respons
traffic
system
thu
deliveri
full
human
dose
anim
model
deem
suitabl
mean
address
potenti
human
toxic
cber
chang
et
al
base
current
clinic
experi
vector
vaccin
candid
rabbit
appear
good
predictor
reactogen
observ
clinic
catanzaro
et
al
yet
suffici
clinic
data
valid
rabbit
appropri
anim
model
howev
vaccin
vector
tuberculosi
malaria
enter
clinic
trial
late
crucel
crucel
data
forthcom
addit
vaccin
describ
herein
also
enter
clinic
trial
genvec
subgroup
c
adenoviru
primarili
enter
cell
bind
coxsacki
adenoviru
receptor
car
subgroup
b
adenoviru
util
membran
cofactor
protein
receptor
tissu
distribut
express
report
small
number
speci
yet
elucid
rabbit
note
appropri
anim
model
hiv
diseas
aid
appropri
model
assess
effect
vaccin
might
subsequ
acquisit
hiv
appropri
model
siv
diseas
would
assess
challengeprotect
model
studi
undertaken
report
herein
intend
model
hiv
acquisit
diseas
progress
vaccin
anim
assess
acut
subacut
intrins
toxic
immunotox
recommend
regulatori
author
specif
unit
state
food
drug
administr
fda
regulatori
jurisdict
clinic
trial
propos
perform
investig
vaccin
vaccin
research
center
vrc
develop
sever
vaccin
candid
prevent
human
diseas
base
adenoviru
vector
platform
candid
vaccin
intend
use
prevent
diseas
caus
virus
includ
human
immunodefici
viru
ebola
marburg
inocul
adenovector
geneinsert
encod
ebola
marburg
protein
result
vivo
express
viral
antigen
strong
antigenspecif
cellular
humor
immun
respons
thu
induc
sullivan
et
al
catanzaro
et
al
sullivan
et
al
sun
et
al
unpublish
data
order
provid
preclin
data
support
safeti
suitabl
candid
vaccin
proceed
human
clinic
test
three
biodistribut
studi
four
repeat
dose
toxicolog
studi
perform
four
adenovectorbas
vaccin
product
describ
herein
addit
two
repeat
dose
toxicolog
studi
report
perform
deliv
adenovector
boost
dna
plasmid
vaccin
prime
biodistribut
safeti
dna
plasmid
vaccin
separ
demonstr
previous
report
sheet
et
al
sheet
et
al
method
studi
design
report
herein
quit
similar
perform
dna
plasmid
vaccin
primari
differ
earlier
studi
dna
plasmid
vaccin
biodistribut
outsid
inject
site
primarili
result
local
reaction
howev
like
adenovector
biodistribut
toxicolog
profil
seem
reflect
platform
dna
plasmid
adenovector
rather
geneinsert
express
adenoviru
vector
vaccin
product
tabl
product
product
describ
catanzaro
et
al
produc
genvec
dosag
genvecproduc
adenovector
express
term
particl
unit
pu
dna
plasmid
prime
use
product
also
previous
describ
sheet
et
al
biodistribut
toxicolog
safeti
given
alon
report
sheet
et
al
sheet
et
al
gene
express
prime
boost
essenti
match
clinic
safeti
data
product
administ
separ
report
catanzaro
et
al
graham
et
al
safeti
data
gener
primeboost
regimen
current
studi
sever
phase
trial
conduct
america
africa
product
ebola
product
combin
adenovector
base
produc
crucel
vector
contain
delet
render
replicationdefect
vector
express
glycoprotein
ebola
sudangulu
zair
strain
mutat
mut
abrog
cytopath
observ
vitro
wildtyp
sequenc
sullivan
et
al
sullivan
et
al
sullivan
et
al
introduc
dosag
crucellproduc
adenovector
express
term
viral
particl
vp
product
product
produc
crucel
base
vector
delet
gene
insert
express
wt
glycoprotein
marburg
viru
angola
strain
product
ebola
product
also
combin
adenovector
base
produc
crucel
express
wildtyp
wt
glycoprotein
ebola
sudangulu
zair
strain
product
differ
product
gene
insert
express
unmut
fulllength
wt
sequenc
product
dnamarburg
product
manufactur
althea
express
marburg
glycoprotein
product
describ
dna
plasmid
backbon
cmvr
promot
describ
sheet
et
al
dna
plasmid
vaccin
product
product
deliv
biojector
previous
describ
sheet
et
al
product
prototyp
vaccin
also
produc
genvec
encod
clade
env
gene
ident
contain
product
gene
insert
adenovir
vector
system
base
instead
vector
contain
delet
region
render
replicationdefect
differ
unit
dose
describ
due
differ
assay
methodolog
manufactur
dosag
genvecproduc
adenovector
express
term
particl
unit
pu
dosag
crucellproduc
adenovector
express
term
viral
particl
vp
case
measur
number
physic
viral
particl
oppos
infecti
titer
sinc
adenovector
replicationdefect
unit
measur
biolog
function
infecti
physic
measur
particl
function
studi
b
c
perform
genelog
gaithersburg
md
bridg
laboratori
involv
inocul
new
zealand
white
rabbit
pu
vp
adenovector
deliv
intramuscularli
im
hind
limb
ml
studi
comparison
made
vaccin
final
formul
buffer
ffb
vaccin
vehicl
anim
inocul
one
time
studi
day
sd
sacrif
sodium
pentobarbit
exsanguin
studi
b
varianc
studi
day
sacrific
studi
base
pragmat
schedul
consider
anim
facil
timepoint
approxim
wk
mo
studi
b
mo
postinocul
mo
time
point
delet
studi
c
design
streamlin
studi
base
prior
experi
follow
organ
collect
biodistribut
analys
blood
gonad
liver
thymu
heart
lung
kidney
spleen
mesenter
lymph
node
right
left
poplit
lymph
node
right
left
iliac
lymph
node
subcuti
inject
site
thigh
muscl
inject
site
bone
marrow
left
femur
brain
pair
organ
process
togeth
except
poplit
iliac
lymph
node
process
separ
tissu
bone
marrow
cell
snap
frozen
liquid
nitrogen
place
steril
vial
store
addit
anim
monitor
morbid
tremor
convuls
saliv
diarrhea
lethargi
coma
atyp
behavior
mortal
twice
daili
clinic
sign
toxic
evalu
skin
fur
characterist
eye
mucou
membran
respiratori
circulatori
autonom
central
nervou
system
somatomotor
behavior
pattern
prior
dose
weekli
sacrific
bodi
weight
taken
prior
dose
weekli
sacrific
fast
food
consumpt
measur
daili
studi
perform
complianc
good
laboratori
practic
glp
regul
cfr
studi
schema
display
tabl
studi
perform
genelog
bridg
laboratori
facil
gaithersburg
md
studi
new
zealand
white
rabbit
per
gender
inocul
intramuscularli
dose
schedul
indic
tabl
dose
split
permit
administr
mlinocul
split
dose
administ
inch
apart
hind
limb
subsequ
dose
deliv
altern
hind
limb
dna
plasmid
prime
hiv
studi
studi
marburg
studi
studi
f
inocul
biojector
describ
sheet
et
al
adenovector
deliv
needleandsyring
studi
number
inocul
determin
consid
propos
potenti
clinic
trial
design
ad
one
addit
inocul
case
primeboost
regimen
one
addit
prime
one
addit
boost
inocul
given
beyond
plan
clinic
order
introduc
marginofsafeti
toxicolog
studi
design
dose
higher
intend
human
dose
clinic
trial
materi
limit
feasibl
highest
propos
clinic
dose
adenoviru
vector
given
studi
half
anim
per
gender
sacrif
immedi
rest
wk
recoveri
final
inocul
see
tabl
sd
anim
monitor
mortal
morbid
cagesid
clinic
observ
describ
draiz
score
bodi
temperatur
bodi
weight
weight
chang
food
consumpt
ophthalmolog
clinic
patholog
hematolog
chemistri
coagul
parametersa
report
tabl
sheet
et
al
addit
fibrinogen
monitor
studi
f
g
inlif
portion
studi
immedi
prior
time
sacrific
necropsi
includ
organ
weight
ratio
gross
histopatholog
tissu
list
tabl
sheet
et
al
sampl
taken
immunogen
assay
elisa
confirm
activ
dose
inocul
ie
dose
confirm
requir
glp
studi
perform
accord
glp
except
immunogen
analys
perform
describ
draiz
score
measur
score
grade
none
reflect
swell
normal
color
score
grade
minim
reflect
slight
swell
indistinct
border
light
pink
indistinct
score
grade
mild
reflect
defin
swell
distinct
border
bright
pink
pale
red
distinct
score
grade
moder
reflect
defin
swell
rais
border
mm
bright
red
distinct
score
grade
sever
reflect
pronounc
swell
rais
border
mm
dark
red
pronounc
statist
analys
repeateddos
toxicolog
studi
bodi
temperatur
bodi
weight
chang
food
consumpt
organ
weight
ratio
clinic
patholog
data
analyz
use
kolmogorovsmirnov
test
normal
leven
median
test
equal
varianc
oneway
analysi
varianc
anova
either
normal
equal
varianc
test
fail
analysi
continu
use
nonparametr
kruskalw
anova
ranktransform
data
probabl
valu
less
twotail
use
critic
level
signific
test
without
introduc
adjust
multipl
analys
statist
analys
conduct
use
sigmastat
statist
softwar
jandel
scientif
san
rafael
ca
concurr
gendermatch
concurr
placebo
control
group
use
comparison
data
case
grouptim
point
n
statist
analysi
perform
multipl
analys
perform
number
analys
clinic
patholog
paramet
demonstr
statist
signific
addit
statist
analys
anova
perform
clinic
patholog
paramet
order
highlight
consist
gender
timepoint
studi
identifi
may
overlook
investig
clinic
correl
differ
note
gener
mg
tissu
process
dna
extract
tissu
subject
enzymat
digest
qiagen
lysi
buffer
proteinas
k
dna
extract
biorobot
workstat
qiagen
use
reagent
protocol
recommend
manufactur
tissu
sampl
includ
run
biorobot
serv
sentinel
control
contamin
concentr
elut
dna
determin
uv
spectrophotometri
adjust
final
concentr
suitabl
qpcr
multiplex
taqman
qpcr
assay
design
target
four
recombin
adenovector
contain
hiv
insert
compos
product
vaccin
primer
probe
design
use
primer
softwar
appli
biosystem
inc
foster
citi
ca
four
forward
primer
use
two
revers
primer
use
probe
taqman
reaction
perform
plate
use
abi
prism
instrument
amplif
target
sequenc
perform
duplic
reaction
contain
genom
dna
gdna
tissu
taqman
univers
pcr
master
mix
appli
biosystem
primer
final
concentr
nm
respect
probe
final
concentr
nm
third
replic
reaction
perform
spike
copi
target
sequenc
monitor
qpcr
inhibit
cycl
condit
min
min
cycl
sec
min
quantif
target
sequenc
specimen
determin
use
standard
curv
plasmid
dna
dilut
background
gdna
isol
anim
standard
templat
control
sentinel
extract
control
background
gdna
control
run
duplic
reaction
assay
perform
characterist
establish
assay
qualifi
use
anim
model
limit
detect
lod
assay
copi
target
sequencemicrogram
gdna
limit
quantif
loq
gdna
qpcr
analys
perform
althea
technolog
inc
san
diego
ca
taqman
qpcr
assay
design
target
adenoviru
vector
sequenc
common
compon
vaccin
primer
probe
design
use
primer
express
softwar
appli
biosystem
forward
primer
use
revers
primer
probe
reaction
perform
plate
use
abi
prism
instrument
amplif
target
sequenc
perform
duplic
reaction
contain
genom
dna
gdna
tissu
taqman
univers
pcr
master
mix
appli
biosystem
primer
probe
final
concentr
nm
nm
respect
third
replic
reaction
perform
spike
copi
target
sequenc
monitor
qpcr
inhibit
cycl
condit
min
min
cycl
sec
min
quantif
target
sequenc
specimen
determin
use
standard
curv
plasmid
dna
dilut
background
gdna
isol
anim
standard
templat
control
sentinel
extract
control
background
gdna
control
run
duplic
reaction
assay
perform
characterist
establish
assay
qualifi
use
anim
model
limit
detect
lod
assay
copi
target
sequenc
per
microgram
gdna
limit
quantif
loq
copi
per
gdna
qpcr
analys
perform
althea
technolog
inc
taqman
qpcr
assay
design
target
adenoviru
type
backbon
vector
hiv
vaccin
primer
probe
design
use
primer
express
softwar
appli
biosystem
forward
primer
use
revers
primer
probe
taqman
reaction
perform
plate
use
abi
instrument
amplif
target
sequenc
perform
duplic
reaction
contain
genom
dna
gdna
tissu
taqman
univers
pcr
master
mix
appli
biosystem
primer
probe
final
concentr
nm
nm
respect
third
replic
reaction
perform
spike
copi
target
sequenc
monitor
qpcr
inhibit
cycl
condit
min
min
cycl
sec
min
quantif
target
sequenc
specimen
determin
use
standard
curv
plasmid
dna
dilut
background
gdna
isol
anim
standard
templat
control
sentinel
extract
control
background
gdna
control
run
duplic
reaction
assay
perform
characterist
establish
assay
qualifi
use
anim
model
limit
detect
lod
assay
copi
target
gdna
limit
quantif
loq
gdna
qpcr
analys
perform
althea
technolog
inc
mean
copi
number
tissu
first
last
time
point
compar
use
wilcoxon
ranksum
test
initi
differ
gender
tissu
time
point
compar
confirm
gender
differ
exist
data
gender
could
pool
analyz
togeth
pvalu
report
figur
optim
concentr
purifi
recombin
antigen
coat
onto
hb
microtit
plate
thermo
labsystem
milford
overnight
detail
tabl
hiv
gag
antigen
purchas
commerci
remaind
antigen
gener
inhous
vrc
plasmid
express
cell
purifi
major
protein
product
plate
wash
block
bsabuff
solut
hr
duplic
well
receiv
rabbit
sera
dilut
incub
hr
wash
remov
nonadher
materi
well
receiv
incub
biotinlabel
antirabbit
iggigaigm
kpl
gaithersburg
md
hr
period
well
wash
receiv
incub
streptavidinhrpo
horseradish
peroxidas
min
room
temperatur
wash
well
receiv
tmb
tetramethylbenzidin
substrat
incub
min
room
temperatur
color
develop
stop
addit
sulfur
acid
absorb
well
read
within
min
nm
minimum
dilut
prevaccin
end
studi
sampl
run
anim
antigen
duplic
well
mean
od
dilut
compar
mean
od
dilut
preimmun
sampl
sera
consid
respons
postvaccin
od
prevaccin
sampl
anim
gener
pattern
adenovector
remain
primarili
site
inocul
muscl
subcuti
traffick
liver
iliac
lymph
node
spleen
distal
organ
includ
remain
absent
gonad
time
number
anim
posit
tissu
copi
number
present
posit
tissu
declin
steadili
demonstr
clearanc
adenovector
two
group
inocul
studi
one
group
receiv
ml
ffb
diluent
im
group
receiv
pu
product
im
ml
anim
surviv
schedul
sacrific
clinic
sign
treatmentrel
toxic
studi
differ
bodi
weight
weight
chang
compar
control
decreas
food
consumpt
hr
follow
vaccin
correl
find
repeat
dose
toxicolog
studi
studi
achiev
statist
signific
male
pcr
result
shown
figur
tabl
two
group
inocul
studi
one
group
receiv
ml
ffb
diluent
im
group
receiv
vp
product
im
ml
anim
surviv
schedul
sacrific
clinic
sign
treatmentrel
toxic
studi
differ
bodi
weight
weight
chang
compar
control
find
gross
patholog
pcr
result
shown
figur
tabl
two
group
inocul
studi
one
group
receiv
ml
ffb
diluent
im
group
receiv
vp
product
im
ml
anim
surviv
schedul
sacrific
clinic
sign
treatmentrel
toxic
studi
differ
bodi
weight
weight
chang
compar
control
pcr
result
shown
figur
tabl
studi
vector
vector
studi
g
bodi
temperatur
elev
period
immedi
postvaccin
figur
mild
fever
note
anoth
studi
vector
deliv
higher
dose
report
cheng
et
al
seen
dose
studi
pu
addit
mean
food
consumpt
diminish
period
immedi
postvaccin
inocul
repeat
initi
inocul
figur
thu
primari
toxic
note
local
draiz
score
histopatholog
revers
revers
system
toxic
fever
food
consumpt
clinic
patholog
paramet
also
note
howev
specif
target
organ
inject
site
affect
grossli
histopatholog
demonstr
vaccin
candid
test
safe
suitabl
investig
clinic
use
dose
puvp
given
intramuscularli
repeat
dose
toxicolog
studi
clinic
patholog
paramet
note
tabl
appear
impact
vaccin
due
occurr
statist
signific
differ
one
gender
one
timepoint
across
studi
statist
significantli
differ
concurr
gendermatch
control
also
outsid
histor
refer
rang
gender
speci
laboratori
addit
paramet
found
statist
significantli
differ
concurr
control
follow
consid
evalu
addit
differ
mean
remain
within
histor
refer
rang
magnitud
direct
differ
clinic
meaning
andor
lack
correl
across
gender
group
timepoint
studi
paramet
eg
clinic
symptom
histopatholog
relat
clinic
patholog
paramet
therefor
find
deem
incident
treatmentrel
report
herein
anim
surviv
schedul
sacrific
except
one
control
femal
studi
f
marburg
found
dead
prior
clinic
observ
treatmentrel
find
note
regard
morbidityclin
observ
ophthalmolog
treatmentrel
find
regard
gross
patholog
note
studi
hiv
primeboost
alon
describ
local
reaction
treatmentrel
gross
patholog
note
studi
e
ebola
f
marburg
g
essenti
impact
deliveri
adenovector
draiz
score
signific
find
seen
relat
dna
plasmid
prime
studi
hiv
primeboost
f
marburg
describ
local
reaction
impact
bodi
weight
studi
hiv
alon
primeboost
e
ebola
f
marburg
note
studi
g
describ
system
reaction
studi
hiv
alon
primeboost
local
reaction
minim
anim
receiv
adenovector
alon
boost
minim
erythema
seen
inject
site
treat
male
control
femal
second
adenovector
inject
given
alon
contrast
primeboost
regimen
vaccin
dna
prime
result
draiz
score
minim
moder
edema
erythema
increas
frequenc
sever
repeat
dose
result
combin
inject
biojector
activ
vaccin
observ
also
occur
control
anim
lower
amount
lesser
degre
find
consist
studi
dna
vaccin
alon
sheet
et
al
boost
adenovector
deliv
needl
syring
inject
increas
frequenc
sever
minim
erythema
andor
edema
treat
anim
draiz
observ
seen
earlier
timepoint
prime
dose
local
reaction
evidenc
howev
clear
treatmentrel
adenovector
alon
primeboost
observ
seen
gross
histopatholog
inject
site
histopatholog
find
inflamm
perineur
tissu
sciatic
nerv
near
inject
site
latter
lesion
consist
chronic
inflammatori
cell
small
macrophag
lymphocyt
connect
tissu
around
sciatic
nerv
adjac
lymphat
blood
capillari
inflamm
result
drain
toward
proxim
lymph
node
distal
inject
site
inject
site
reaction
less
frequenc
sever
recoveri
sacrific
anim
immedi
sacrific
anim
adenovector
alon
primeboost
regimen
demonstr
revers
inject
site
reaction
treatmentrel
find
observ
grossli
histopatholog
studi
e
ebola
local
reaction
minim
moder
assess
sole
histopatholog
gross
patholog
draiz
score
differ
note
treat
control
anim
inflamm
site
inocul
greater
frequenc
treat
anim
inflamm
note
site
inject
adjac
muscl
around
blood
vessel
lymphat
surround
proxim
sciatic
nerv
recoveri
sacrific
inflamm
observ
lower
frequenc
lesser
intens
immedi
sacrific
demonstr
revers
studi
f
marburg
minim
moder
edema
minim
mild
erythema
note
control
treat
anim
increas
incid
andor
durat
follow
sever
vaccin
treat
anim
reaction
associ
dna
vaccin
deliv
biojector
minim
edema
erythema
note
follow
adenovector
deliveri
histopatholog
inject
site
find
observ
frequent
treat
anim
mostli
minim
mild
inflamm
though
moder
inflamm
note
inject
site
two
treat
femal
minim
inflamm
still
note
inject
site
frequent
treat
anim
demonstr
revers
reaction
histopatholog
find
outsid
site
inject
consid
incident
occur
frequent
speci
seen
control
treat
anim
studi
g
minim
moder
local
reaction
note
inject
site
histopatholog
slightli
sever
frequent
treat
anim
versu
control
revers
demonstr
minor
anim
evid
ongo
reaction
approxim
equival
treat
anim
control
histopatholog
differ
group
note
treatmentrel
draiz
find
bodi
temperatur
studi
hiv
alon
primeboost
system
reaction
adenovector
vaccin
note
mild
fever
seen
hr
subsequ
initi
second
adenovector
vaccin
adenovector
arm
reaction
resolv
hr
likewis
fever
seen
treat
male
femal
hr
subsequ
initi
first
hr
treat
femal
second
adenovector
boost
primeboost
treat
anim
fever
resolv
hr
initi
hr
second
treat
adenovector
boost
figur
furthermor
system
reaction
adenovector
vaccin
note
mild
fever
seen
hr
follow
first
adenovector
boost
return
normal
hr
fever
note
follow
second
adenovector
boost
although
mean
treat
male
statist
significantli
higher
control
hr
postdos
remain
well
within
normal
temperatur
rang
speci
figur
studi
e
ebola
mild
fever
also
seen
first
inocul
hr
postinocul
muttreat
wttreat
femal
begin
show
significantli
increas
bodi
temperatur
compar
control
femal
hr
postinocul
treat
anim
elev
bodi
temperatur
group
mean
approach
slightli
exceed
fever
resolv
hr
postinocul
statist
significantli
increas
bodi
temperatur
note
time
remain
well
within
normal
bodi
temperatur
rabbit
lee
consid
incident
fever
observ
follow
second
third
inocul
figur
studi
f
marburg
mild
fever
seen
hr
follow
first
adenovector
boost
return
normal
hr
fever
note
follow
second
adenovector
boost
although
mean
treat
male
statist
significantli
higher
control
hr
postdos
remain
well
within
normal
temperatur
rang
speci
figur
studi
g
treatmentrel
effect
seen
regard
bodi
temperatur
dosag
test
contrast
consist
find
mild
fever
follow
deliveri
clearest
differ
reactogen
two
vector
platform
food
consumpt
bodi
weight
chang
studi
hiv
alon
primeboost
system
reaction
note
food
consumpt
also
less
treat
anim
hr
adenovector
alon
primeboost
hr
primeboost
follow
adenovector
vaccin
resolv
figur
revers
decreas
food
consumpt
result
differ
bodi
weight
chang
male
femal
inocul
adenovector
alon
treat
male
primeboost
regimen
howev
possibl
primeboost
treatment
effect
seen
bodi
weight
chang
treat
femal
differ
began
note
earli
studi
day
sd
prime
phase
becam
statist
significantli
differ
control
femal
sd
bodi
weight
sd
bodi
weight
chang
primeboost
treat
femal
anim
continu
gain
weight
throughout
studi
gain
less
weight
control
whether
reflect
biolog
variabl
among
anim
actual
treatmentrel
effect
unclear
studi
e
ebola
food
consumpt
also
less
treat
anim
compar
control
figur
statist
signific
decreas
seen
treat
group
muttreat
male
muttreat
femal
wttreat
male
wttreat
femal
first
hr
first
inocul
fast
blood
draw
food
consumpt
measur
howev
remain
statist
significantli
decreas
food
consumpt
treat
group
although
decreas
muttreat
achiev
statist
signific
furthermor
wttreat
femal
continu
statist
significantli
decreas
food
consumpt
addit
one
control
male
one
wttreat
femal
supplement
respect
fluid
food
due
low
food
consumpt
second
inocul
treat
anim
statist
signific
mean
decreas
compar
control
inocul
treat
anim
recov
normal
base
comparison
control
food
consumpt
food
consumpt
measur
due
fast
blood
draw
final
third
inocul
muttreat
male
statist
signific
decreas
incid
statist
significantli
differ
food
consumpt
note
follow
decreas
muttreat
muttreat
wttreat
respect
wttreat
relationship
treatment
addit
incid
decreas
food
consumpt
remot
time
vaccin
without
consist
pattern
treatment
groupsgend
less
clear
might
incident
although
direct
ie
decreas
note
howev
differ
base
animalsgroup
rather
animalsgroup
due
sacrific
half
anim
individu
anim
variat
could
potenti
impact
mean
smaller
group
size
differ
seen
treat
control
anim
term
bodi
weight
even
though
effect
bodi
weight
chang
treat
anim
decreas
bodi
weight
chang
compar
control
achiev
statist
signific
although
decreas
achiev
statist
signific
muttreat
femal
furthermor
muttreat
femal
statist
significantli
decreas
bodi
weight
chang
decreas
bodi
weight
chang
weight
loss
lesser
bodi
weight
gain
time
period
result
differ
mean
bodi
weight
group
decreas
bodi
weight
chang
probabl
reflect
decreas
food
consumpt
occur
immedi
postinocul
describ
studi
f
marburg
although
statist
signific
differ
food
consumpt
treat
control
anim
dna
vaccin
prime
phase
studi
magnitud
differ
small
occurr
random
time
ie
necessarili
immedi
follow
vaccin
contrast
day
follow
adenovector
boost
mean
food
consumpt
clear
mark
treatmentrel
impact
follow
treat
follow
first
adenovector
boost
treat
follow
first
adenovector
boost
treat
follow
second
adenovector
boost
treat
follow
second
adenovector
boost
mark
impact
food
consumpt
prolong
sever
follow
first
adenovector
boost
take
treat
male
return
normal
food
consumpt
treat
femal
figur
bodi
weight
chang
affect
treatment
male
though
femal
like
reflect
effect
food
consumpt
follow
treatment
describ
dna
prime
phase
statist
signific
differ
note
mean
bodi
weight
chang
decreas
treat
femal
increas
treat
male
like
reflect
biolog
variabl
rather
treatment
effect
contrast
subsequ
adenovector
deliveri
treat
male
statist
signific
decreas
mean
bodi
weight
chang
weight
loss
g
sd
vs
weight
gain
g
statist
signific
increas
mean
bodi
weight
chang
g
vs
g
statist
signific
differ
femal
mean
bodi
weight
chang
timefram
subsequ
adenovector
vaccin
studyg
mild
system
reaction
note
treat
anim
slightli
lower
increas
bodi
weight
concord
lower
weight
chang
food
consumpt
control
regard
food
consumpt
transient
decreas
gender
note
hr
follow
second
adenovector
deliveri
femal
hr
follow
third
adenovector
deliveri
male
hr
follow
third
adenovector
deliveri
suggest
increas
reactogen
repeat
dose
figur
clear
distinct
vector
demonstr
decreas
sever
paramet
repeat
dose
repeat
dose
toxicolog
studi
mani
differ
note
control
treat
group
clinic
chemistri
hematolog
paramet
differ
unclear
relationship
treatment
either
remain
within
normal
histor
control
rang
speci
laboratori
even
though
statist
significantli
differ
match
control
anim
studi
outsid
normal
rang
differ
control
anim
studi
consist
gender
across
timepoint
clinic
patholog
paramet
consist
differ
control
gender
across
timepoint
studi
report
tabl
none
find
appear
correl
clinic
observ
gross
histopatholog
find
thu
clinic
relev
uncertain
presum
demonstr
inflamm
reflect
immun
respons
vaccin
serum
chemistri
appear
impact
treatment
adenovector
vaccin
includ
cholesterol
triglycerid
period
follow
initi
inocul
globulin
ag
ratio
follow
inocul
serum
globulin
level
commensur
ag
ratio
may
reflect
intend
immun
respons
vaccin
fact
case
immunogen
measur
elisa
demonstr
studi
endpoint
cholesterol
triglycerid
elev
follow
initi
adenovector
inocul
case
see
descript
studi
f
except
may
simpli
reflect
inflamm
respons
recognit
express
deliv
adenovector
antigen
liver
enzym
alt
ast
alkalin
phosphatas
timepoint
either
statist
significantli
differ
concurr
gendermatch
control
differ
direct
indic
liver
toxic
eg
treat
anim
lower
valu
control
furthermor
paramet
sporad
differ
control
provid
consist
pattern
contrast
studi
e
ebola
cholesterol
triglycerid
elev
first
adenovector
dose
studi
f
marburg
paramet
unaffect
adenovector
boost
howev
triglycerid
cholesterol
elev
post
dna
dose
treat
male
time
liver
function
test
unaffect
howev
male
elev
ast
compar
concurr
control
remain
within
lower
half
normal
rang
post
adenovector
dose
treat
male
elev
mean
alt
treat
femal
lower
mean
ast
postsecond
adenovector
dose
treat
male
elev
mean
ast
given
inconsist
result
lack
liver
histopatholog
note
also
seen
control
appear
liver
toxic
hematolog
paramet
appear
impact
adenovector
deliveri
includ
hemoglobin
hematocrit
platelet
mean
platelet
volum
mpv
surpris
hemoglobin
hematocrit
may
decreas
time
studi
given
anim
frequent
blooddraw
howev
appear
consist
pattern
comparison
concurr
gendermatch
control
anim
receiv
adenovector
effect
seen
multipl
timepoint
across
particular
studi
mean
valu
sometim
fall
outsid
histor
refer
rang
magnitud
differ
lower
bound
refer
rang
mean
valu
observ
small
like
clinic
signific
regard
coagul
paramet
appear
impact
intramuscular
adenovector
deliveri
follow
prothrombin
time
frequent
shorten
variou
timepoint
postvaccin
clinic
relev
shorten
time
activ
partial
thromboplastin
time
aptt
frequent
prolong
mani
time
outsid
histor
refer
rang
fibrinogen
also
frequent
elev
sometim
outsid
histor
refer
rang
effect
appear
revers
gener
observ
recoveri
sacrific
timepoint
see
tabl
effect
interpret
reflect
acut
inflamm
due
immun
respons
vaccin
inflamm
associ
intramuscular
deliveri
studi
hiv
primeboost
immunogen
result
demonstr
vaccin
anim
seroconvert
enva
envb
envc
gag
antigen
adenovector
alon
primeboost
arm
endpoint
titer
determin
vaccin
anim
seroposit
dilut
placeborecipi
seroconvert
result
demonstr
activ
dose
vaccin
deliv
test
anim
respons
made
plasmidand
adenovectorexpress
compon
vaccin
studi
e
ebola
immunogen
result
demonstr
vaccin
anim
seroconvert
ebola
antigen
vaccin
endpoint
titer
determin
vaccin
anim
seroposit
dilut
placeborecipi
seroconvert
result
demonstr
activ
dose
vaccin
deliv
test
anim
respond
adenovectorexpress
compon
vaccin
studi
f
marburg
immunogen
result
provid
evid
activ
dose
deliv
treat
anim
placeborecipi
anim
studi
treat
anim
seroconvert
marburg
glycoprotein
titer
exceed
primeboost
vaccin
placeborecipi
remain
seroneg
studi
g
immunogen
result
demonstr
vaccin
anim
seroconvert
enva
antigen
endpoint
titer
determin
test
perform
sera
dilut
vaccin
anim
remain
seroposit
dilut
placeborecipi
seroconvert
result
demonstr
activ
dose
vaccin
deliv
test
anim
studi
hiv
primeboost
aspect
studi
conduct
accord
glp
except
immunogen
analys
deviat
report
would
impact
integr
studi
conclus
drawn
howev
primeboost
control
anim
receiv
dna
plasmid
placebo
inocul
needl
syring
rather
biojector
specifi
make
comparison
control
treat
anim
inject
site
draiz
find
timepoint
immedi
subsequ
inocul
less
relev
invalid
find
treat
anim
relev
safeti
vaccin
intend
deliveri
devic
studi
e
ebola
aspect
conduct
accord
glp
except
immunogen
analys
certif
analysi
coa
stabil
perform
per
good
research
practic
deviat
report
would
impact
integr
studi
conclus
drawn
studi
f
marburg
aspect
conduct
accord
glp
except
coa
stabil
analys
met
good
manufactur
practic
gmp
standard
immunogen
analys
perform
laboratori
follow
glp
nonvalid
method
compar
valid
method
also
perform
laboratori
deviat
report
would
impact
integr
studi
conclus
drawn
studi
g
aspect
conduct
accord
glp
except
immunogen
analys
perform
research
set
deviat
report
impact
integr
studi
conclus
drawn
adenovector
base
serotyp
subgroup
c
subgroup
b
despit
differ
express
transgen
insert
manufactur
construct
similar
consist
pattern
biodistribut
clearanc
dose
particl
unit
viral
particl
pu
vp
deliv
intramuscularli
needleandsyring
differ
unit
dose
describ
due
differ
assay
methodolog
manufactur
adenovector
remain
larg
site
inject
extens
traffic
outsid
site
vector
biodistribut
spleen
liver
wherea
vector
biodistribut
spleen
iliac
lymph
node
note
cellular
receptor
util
virus
differ
predomin
bind
car
coxsacki
adenoviru
receptor
wherea
bind
membran
cofactor
protein
howev
given
intramuscularli
vector
biodistribut
wide
eg
traffic
gonad
furthermor
seen
clear
site
biodistribut
cours
studi
fewer
anim
posit
tissu
fewer
posit
tissu
posit
anim
low
copi
number
rang
remain
tissu
remain
posit
studi
endpoint
despit
initi
deliveri
puvp
appropri
analys
perform
yet
determin
rather
adenovector
actual
distribut
tissu
directli
seem
like
adenovector
deliv
muscl
may
transduc
antigenpres
cell
apc
resid
apc
like
traffick
lymphoid
organ
highli
perfus
liver
hypothes
fact
adenovector
biodistribut
throughout
bodi
transduc
cell
inject
site
traffic
specif
organ
hypothesi
consist
recent
find
chimp
adenoviru
vector
found
predomin
tcell
spleen
time
inocul
tatsi
et
al
nevertheless
biodistribut
studi
suggest
potenti
target
organ
toxic
might
spleen
liver
andor
lymph
node
well
site
inject
gross
histopatholog
differ
control
treat
anim
found
organ
repeat
dose
toxicolog
studi
except
site
inject
nonetheless
clinic
patholog
paramet
relat
liver
function
appear
impact
adenovector
deliveri
paramet
impact
deliveri
traffick
liver
would
appear
liver
functionrel
clinic
patholog
paramet
direct
toxic
effect
adenovector
deliveri
like
repres
secondari
effect
inflamm
immun
respons
adenovector
andor
express
gene
insert
repeat
dose
toxicolog
studi
puvp
demonstr
similar
consist
pattern
toxic
adenovector
base
despit
differ
express
transgen
insert
manufactur
construct
whether
given
boost
dna
plasmid
vaccin
prime
alon
adenovector
result
report
herein
came
two
differ
manufactur
contain
differ
adenoviru
gene
delet
delet
partial
repres
differ
construct
addit
vector
manufactur
growth
differ
cell
substrat
purifi
follow
differ
product
method
furthermor
express
transgen
insert
differ
virus
includ
envelop
glycoprotein
gag
polymeras
gene
first
differ
clade
ebola
glycoprotein
contain
either
point
mutat
abrog
cellular
toxic
note
vitro
sullivan
et
al
wt
construct
marburg
glycoprotein
nevertheless
toxicolog
profil
consist
despit
differ
express
transgen
insert
manufactur
construct
product
method
pattern
allow
predict
expect
clinic
reactogen
similar
viral
vaccin
product
base
identifi
toxic
profil
adenovector
vaccin
given
intramuscularli
alon
boost
dna
plasmid
vaccin
prime
limit
revers
local
draiz
score
histopatholog
site
inocul
system
reactogen
fever
decreas
food
consumpt
period
immedi
follow
vaccin
furthermor
certain
clinic
patholog
paramet
impact
suggest
inflamm
relationship
vaccin
note
effect
seen
consist
gender
appar
gender
differ
clinic
patholog
paramet
differ
gender
consist
across
studi
timepoint
suggest
incident
rather
real
genderrel
differ
must
kept
mind
analyz
appar
differ
despit
number
paramet
compar
multipl
timepoint
adjust
multipl
perform
statist
analys
stringent
mean
identifi
potenti
safeti
signal
importantli
treatmentrel
differ
paramet
seen
consist
across
timepoint
studi
note
gender
one
timepoint
anoth
timepoint
data
suggest
may
slightli
less
reactogen
system
similar
dose
febril
reaction
seen
vector
studi
report
herein
seen
dose
vp
given
cheng
et
al
unpublish
result
furthermor
impact
food
consumpt
anoth
marker
system
reactogen
seen
follow
initi
inject
repeat
dose
wherea
vector
impact
note
follow
even
initi
inocul
perhap
mark
initi
inocul
howev
consist
pattern
toxic
seen
clinic
patholog
paramet
anoth
marker
system
reactogen
inject
site
local
reactogen
given
enter
cell
differ
cellular
receptor
one
might
predict
target
organ
cell
therefor
toxic
profil
would
differ
fact
found
toxic
profil
quit
similar
consist
although
may
slightli
less
reactogen
system
dose
test
consist
recent
report
demonstr
even
fiber
shaft
vector
modifi
elimin
bind
primari
car
secondari
integrin
rgd
receptor
switch
fiber
shaft
util
receptor
retain
abil
transfect
heparinsensit
receptor
sever
dendrit
cell
mononuclear
cell
subtyp
retain
pyrogen
cheng
et
al
induc
adapt
immun
toxic
pyrogen
given
liver
identifi
biodistribut
studi
potenti
target
organ
toxic
note
evid
treatmentrel
liver
patholog
either
grossli
histopatholog
thu
conclud
liver
toxic
occur
adenovector
deliv
intramuscularli
dose
puvp
elev
cholesterol
triglycerid
simpli
reflect
inflammatori
respons
vaccin
importantli
despit
report
liver
toxic
similar
higher
dose
adenovector
deliv
rout
intramuscular
rout
studi
harvey
et
al
raper
et
al
note
particular
consist
impact
vaccin
liver
either
liver
function
test
alt
ast
alkalin
phosphatas
gross
histopatholog
discuss
particularli
concern
whether
might
impact
hematolog
paramet
given
express
antigen
ebola
marburg
glycoprotein
virus
caus
hemorrhag
diseas
howev
effect
also
seen
ebola
glycoprotein
point
mutat
introduc
abrog
cellular
cytotox
observ
vitro
antigen
envelop
clade
b
c
clade
b
gag
clade
b
pol
thu
conclud
like
affect
paramet
effect
hemoglobin
hematocrit
relat
adenovector
deliveri
express
transgen
antigen
furthermor
regard
platelet
mpv
although
studi
hiv
alon
primeboost
e
ebola
extrem
mild
thrombocytopenia
note
initi
adenovector
inocul
studi
e
ebola
mean
valu
fell
slightli
outsid
histor
refer
rang
sever
slight
like
clinic
meaning
consist
find
adenovector
deliveri
intramuscularli
result
shorten
prothrombin
time
shorten
time
clinic
meaning
conclud
result
reflect
coagul
abnorm
particular
note
consist
observ
prolong
activ
partial
thromboplastin
time
aptt
also
observ
clinic
associ
adenoviru
infect
adenovector
deliveri
beck
et
al
jaeger
et
al
malaeb
et
al
unpublish
data
case
rather
vivo
coagul
abnorm
found
vitro
assay
impact
develop
lupu
anticoagul
antiphospholipid
antibodi
infect
inocul
individu
whether
also
happen
case
rabbit
rabbit
aptt
assay
uncertain
possibl
prolong
aptt
repres
clinic
benign
effect
transient
inflammationinduc
antiphospholipid
antibodi
vitro
assay
adenovector
deliv
intravascularli
may
bind
variou
coagul
factor
parker
et
al
clinic
evid
coagul
abnorm
studi
therefor
suggest
adenovector
deliveri
intramuscularli
induc
clinicallyrelev
coagul
abnorm
aptt
assay
indirectli
detect
transient
rise
antiphospholipid
antibodi
byproduct
vaccineinduc
inflamm
immun
respons
elev
fibrinogen
valu
like
reflect
vaccineinduc
inflammatori
respons
support
interpret
believ
data
suggest
whether
adenovector
given
alon
dna
primeadenovector
boost
regimen
toxic
profil
consist
similar
suggest
prior
prime
dna
vaccin
neither
abrog
enhanc
significantli
adenovectorassoci
toxic
sinc
conclud
toxic
primarili
relat
adenovector
rather
express
transgen
would
share
prime
boost
understand
toxic
note
essenti
mild
revers
data
suggest
toxicolog
studi
individu
vector
alon
adequ
predict
expect
pattern
toxic
support
futur
use
relat
product
primeboost
clinic
protocol
without
need
delay
clinic
develop
undertak
addit
toxicolog
studi
acceler
clinic
develop
much
month
depend
number
prime
boost
would
given
taken
togeth
data
suggest
biodistribut
toxicolog
profil
adenovector
vaccin
determin
larg
platform
express
geneinsert
gene
ebola
marburg
manufactur
construct
vector
delet
partial
manufactur
either
crucel
genvec
whether
given
alon
boost
dna
plasmid
vaccin
prime
data
demonstr
vector
deliv
intramuscularli
vaccin
express
system
dose
puvp
safe
suitabl
human
clinic
trial
healthi
volunt
fact
result
studi
alreadi
submit
fda
regulatori
author
around
globe
support
conduct
phase
phase
clinic
trial
clinic
data
ongo
complet
vaccin
trial
candid
valid
system
toxic
seen
rabbit
mimick
human
fever
malais
myalgia
chill
given
dose
lower
dose
reduc
frequenc
andor
sever
system
reaction
human
catanzaro
et
al
unpublish
data
present
insuffici
clinic
data
vector
valid
rabbit
model
howev
data
emerg
preliminari
data
far
consist
preclin
find
take
similar
vector
rabbit
suggest
rabbit
model
also
valid
despit
fact
use
differ
cellular
receptor
three
goal
fda
expect
preclin
toxicolog
studi
accomplish
includ
follow
recommend
initi
safe
start
dose
dose
regimen
human
subject
identifi
potenti
target
organ
toxic
relat
product
help
determin
accept
riskbenefit
ratio
human
subject
feel
goal
accomplish
adenovector
type
vaccin
deliv
intramuscularli
dose
vppu
studi
report
herein
bodi
data
progress
clinic
develop
futur
candid
signific
save
time
resourc
repetit
studi
includ
addit
studi
primeboost
regimen
avoid
safeti
new
candid
support
studi
alreadi
perform
candid
base
similar
platform
acceler
develop
vaccin
candid
crucial
given
enorm
public
health
burden
hivaid
everpres
threat
bioterror
agent
ebola
marburg
virus
urgenc
address
emerg
infect
sudden
acut
respiratori
syndrom
sar
west
nile
viru
pandem
influenza
biodistribut
result
box
whisker
plot
show
copi
number
present
variou
tissu
control
treat
anim
studi
b
c
pvalu
report
comparison
first
last
time
point
treat
group
demonstr
clearanc
vector
tissu
time
cours
studi
bodi
temperatur
immedi
postvaccin
period
studi
e
f
g
mean
bodi
temperatur
compar
gendermatch
control
differ
signific
p
level
note
asterisk
adjust
made
account
multipl
stringent
detect
potenti
safeti
signal
group
compar
indic
line
bar
error
bar
reflect
standard
deviat
time
point
mark
taken
hr
postinocul
hpi
studi
day
food
consumpt
immedi
postvaccin
period
studi
e
f
g
mean
food
consumpt
compar
gendermatch
control
differ
signific
p
level
note
asterisk
adjust
made
account
multipl
stringent
detect
potenti
safeti
signal
group
compar
indic
line
bar
error
bar
reflect
standard
deviat
paramet
measur
studi
day
anim
fast
blood
draw
quantifi
posit
pcr
result
tissu
studi
final
studi
timepoint
node
esenter
lymph
node
lymph
node
studi
placebo
